Exact Sciences Corporation Exact Sciences Corporation

Exact Sciences Corporation

EXAS

Rang în acțiuni #1157
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
Preț acțiune
$104.91
Ultima sincronizare: 2026-03-23
Capitalizare de piață
$20.03B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
65.45%
Țară
US
Tranzacționează Exact Sciences Corporation (EXAS)

Categorie

Healthcare
Venituri pentru Exact Sciences Corporation (EXAS)
Venituri în Dec 2025 TTM: $3.25B
Conform celor mai recente rapoarte financiare ale Exact Sciences Corporation, venitul actual al companiei (TTM) este $3.25B. În anul 2024, compania a avut un venit de $2.76B o creștere față de venitul din anul 2023, care a fost de $2.50B. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Exact Sciences Corporation din 2000 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
2026 (TTM) $3.25B 0.00%
2025 $3.25B 17.69%
2024 $2.76B 10.37%
2023 $2.50B 19.93%
2022 $2.08B 17.95%
2021 $1.77B 18.49%
2020 $1.49B 70.19%
2019 $876.29M 92.82%
2018 $454.46M 70.86%
2017 $265.99M 167.66%
2016 $99.38M 151.99%
2015 $39.44M 2,093.38%
2014 $1.80M -56.61%
2013 $4.14M 0.00%
2012 $4.14M -0.46%
2011 $4.16M -22.10%
2010 $5.34M 12.32%
2009 $4.76M -648.79%
2008 $-867.00K -129.54%
2007 $2.94M -38.21%
2006 $4.75M 11.76%
2005 $4.25M -13.88%
2004 $4.94M 70.11%
2003 $2.90M 223.41%
2002 $897.00K 1,663.32%
2001 $50.87K 0.00%
2000 0.00 0.00%
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
$46.34B 1,327.04%
US
$25.11B 673.24%
US
$2.71B -16.63%
US
- -
CN
$7.37B 127.04%
US